Gelonghui October 9th 丨Lisheng Pharmaceutical (002393.SZ) announced that it previously revealed that the company plans to publicly list and transfer 15% of the shares held by the participating company Tianjin Pharmaceutical Group Finance Co., Ltd. (the “target company” or “finance company”) at the Tianjin Property Exchange Center at a price of RMB 87.823,386 million. The equity transfer was publicly listed at the Tianjin Property Exchange Center from August 28, 2023 to September 22, 2023. During the listing period, only one company signed up for delisting, namely Jinyao Da Rentang Group Co., Ltd. (“Jinyao Da Rentang” for short). As the intended transferee, it plans to delist and transfer 15% of the shares of the finance company at a price of RMB 87.823,800. The company plans to sign a “Property Rights Transaction Contract” with Jinyao Da Rentang.
The 28th meeting of the 7th board of directors of the company held on October 9, 2023, reviewed and passed the “Proposal on Public Listing and Transfer of 15% Shares and Related Transactions of Tianjin Pharmaceutical Group Finance Co., Ltd.” with 6 votes in agreement, 0 against, and 0 abstentions. Since Jin Pharmaceutical Da Rentang is an enterprise controlled by a joint venture which is an indirect controlling shareholder of our company, this transaction constitutes a related transaction according to the relevant provisions of the “Shenzhen Stock Exchange Stock Listing Rules”.